Dyslipidemia and gallbladder diseases are two current anomalies observed in patients
suffering from the metabolic syndrome and type 2 diabetes. The bile acid-activated nuclear
receptor farnesoid X receptor (FXR) controls bile acid as well as lipid metabolism. Recent
observations indicate a role for FXR also in carbohydrate metabolism. Hepatic FXR
expression is altered in diabetic animal models in vivo and regulated by hormones and
nutrients in vitro. At the molecular level, FXR activation modifies the transcriptional activity of …